Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo

Entera Bio

Status and phase: Active, not recruiting; Phase 2; Phase 1

Conditions: Osteoporosis; Other Disease; Fractures, Bone; Hypoparathyroidism

Treatments: Drug: EBP05; Drug: EBP11; Drug: EBP22; Drug: Forteo 20 mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT05965167

ENT-11-2023

Details and patient eligibility

About

The purpose of this study is to characterize and compare the pharmacokinetics of hPTH(1 34) after treatment with a modified oral formulation (EBP11 and EBP22) versus two dose levels of Entera Bio's extensively studied oral EBP05 1.5 mg and 2.5 mg as well as the commercial Forteo 0.02 mg subcutaneous injection.

Enrollment: 45 estimated patients

Sex: Male

Ages: 18 to 35 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Healthy male subjects, 18 - 35 years of age, inclusive, at screening.
2. Continuous nonsmoker who has not used nicotine containing products (including e-cigarettes, vapors, etc.) for at least 12 months prior to first dosing and throughout the study, based on subject self-reporting.
3. Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at screening.
4. Medically healthy with no clinically significant medical condition, physical examination, laboratory profiles, vital signs, orthostatic vital sign measurements, or ECGs, as deemed by the PI or designee to be relevant to the study and does not pose an additional risk to the subject by their participation in the study.
5. Understands the study procedures described in the Informed Consent Form (ICF), be willing and able to comply with the protocol, and provides written consent.

Exclusion criteria

1. History or current condition of mental instability or cognitive impairment that, in the opinion of the investigator, could compromise the validity of informed consent, compromise the safety of the participant, or lead to nonadherence with the study protocol or inability to conduct the study procedures.

2. Active gastrointestinal inflammatory disorder, gastrointestinal motility disorders, and chronic gastritis, including but not limited to: ulcerative colitis, Crohn's disease, irritable bowel syndrome, short bowel syndrome, celiac disease, gastroparesis, that may affect drug bioavailability.

3. Any conditions or factors that, in the judgment of the PI or designee, somehow may impact gastrointestinal absorption, distribution or metabolism of parathyroid hormone analogues, or known to potentiate or predispose to undesired effects.

4. History of significant gastrointestinal, liver or kidney disease, or gastrointestinal surgery (including bariatric surgery, or any other interventional procedures with stomach and intestinal tract) that may affect either drug bioavailability, or hPTH(1-34) or SNAC metabolism.

5. History or presence of alcohol or drug abuse or positive urine drug or blood alcohol results at screening.

6. Known allergies or sensitivities to components of the Study Medication (e.g. soy) or known hypersensitivity to PTH or hPTH(1-34).

7. History or presence of clinically significant:

   • Urolithiasis;
   • Angina at Screening, in the opinion of the PI;
   • Hypocalcemia or hypercalcemia at screening;
   • Personal or family history of congenital long QT syndrome or known family history of sudden death.

8. Subjects with ECG findings deemed abnormal with clinical significance by the PI or designee at screening for the following:

   • QTcF interval > 470 msec;
   • PR > 220 msec;
   • QRS > 120 msec.

9. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).

10. Seated blood pressure is less than 90 systolic or 40 diastolic mmHg or greater than 140 systolic or 90 diastolic mmHg at screening;

11. Orthostatic vital sign results with a decrease in systolic > 20 mmHg or decrease in diastolic > 10 mm Hg, and/or increase in heart rate of > 20 beats per minute at screening or Day 1 check-in.

12. Seated heart rate is lower than 50 bpm or higher than 99 bpm at screening (when clinically significant as determined by PI).

13. Estimated creatinine clearance < 80 mL/min at screening

14. Unable to refrain from or anticipates the use of:

    • Any drug, including prescription and nonprescription medications, herbal remedies, or vitamin supplements that should be taken on the treatment visit day before the dosing of Study Medication and 2 hours after the dosing of Study Medication.
    • H2 blocker or PPI or antacid (including prescription and nonprescription) three days before the dosing of the Study Medication and 2 hours after the dosing of Study Medication.

15. Donation of blood or significant blood loss within 56 days prior to first dosing.

16. Hemoglobin levels below 13 g/dL at screening or at in screening test done during the study.

17. Plasma donation within 7 days prior to first dosing.

18. Participation in another interventional clinical study within 30 days prior to screening visit.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

45 participants in 14 patient groups

Treatment A EBP05 2.5 mg

Experimental group

Description:

Single dose of oral EBP05 2.5 mg

Treatment:

Drug: EBP05

Treatment B EBP05 1.5 mg

Experimental group

Description:

Single dose of oral EBP05 1.5 mg

Treatment:

Drug: EBP05

Treatment C Forteo 20 mg

Experimental group

Description:

Single SC injection of Forteo 0.02 mg

Treatment:

Drug: Forteo 20 mg

Treatment D EBP11 1.5 mg

Experimental group

Description:

Single dose of oral EBP11 1.5 mg

Treatment:

Drug: EBP11

Treatment E EBP11 BID (dose determined after IA)

Experimental group

Description:

Based on PK data from 1st Interim Analysis BID administration of oral EBP11. The selected BID dose to be administered will be either 1.5, 2.0 or 2.5 mg.

Treatment:

Drug: EBP11

Treatment F EBP11 BID (dose determined after IA)

Experimental group

Description:

BID administration of oral EBP11 tablets 1.5 mg tablets (3 x 0.5 mg tablets) as first dose and 2.5 mg (5 x 0.5 mg tablets) as second dose.

Treatment:

Drug: EBP11

Treatment G EBP11 1.5 mg

Experimental group

Description:

Single dose of oral EBP11 1.5 mg

Treatment:

Drug: EBP11

Treatment I EBP22 1.5 mg

Experimental group

Description:

Single dose of oral EBP22 1.5 mg

Treatment:

Drug: EBP22

Treatment J EBP22 1.5 mg

Experimental group

Description:

Single dose of oral EBP22 1.5 mg

Treatment:

Drug: EBP22

Treatment K oral EBP formulation determined based on IA results

Experimental group

Description:

Single dose of oral 1.5 mg of the selected oral formulation (EBP11 or EBP22) based on the results of all Cohort 1 and 2 Interim Analyses

Treatment:

Drug: EBP22

Drug: EBP11

Treatment L BID of oral EBP formulation determined based on IA results

Experimental group

Description:

BID dose of oral 1.5 mg of the selected oral formulation (EBP11 or EBP22) based on the results of all Cohort 1 and 2 Interim Analyses

Treatment:

Drug: EBP22

Drug: EBP11

Treatment M BID of EBP05 2.5 mg

Experimental group

Description:

BID dose of oral EBP05 2.5 mg

Treatment:

Drug: EBP05

Treatment N single dose of Treatment K

Experimental group

Description:

Single dose of Treatment K

Treatment:

Drug: EBP22

Drug: EBP11

Treatment H EBP22 2.5 mg (5 x 0.5 mg).

Experimental group

Description:

Singe dose of oral EBP22 2.5 mg (5 x 0.5 mg).

Treatment:

Drug: EBP22